Fennec's Pedmark To Reduce Risk Of Ototoxicity Associated With Cisplatin Scores FDA Nod

Fennec Pharmaceuticals Inc. (FENC, FRX) said on Wednesday that the FDA has approved Pedmark to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors.

Pedmark is the first and only FDA approved therapy for the above indication, an area of significant unmet medical need.

In Europe, the drug, under the brand name PEDMARQSI, is currently under evaluation by the European Medicines Agency.

FENC closed Tuesday's trading at $7.63, up 15.78%. In pre-market trading Wednesday, the stock is up 0.13% at $7.64.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Stocks fluctuated in morning trading on Friday before once again coming under pressure over the course of the afternoon. The major averages extended the sharp pullback seen on Thursday, ending the session at their lowest closing levels since late 2020. Consumer sentiment in the U.S. improved by less than initially estimated in the month of September, according to revised data released by the University of Michigan on Friday. The University of Michigan said the consumer sentiment index for September was downwardly revised to 58.6 from the preliminary estimate of 59.5. Chicago-area business activity unexpectedly contracted in the month of September, according to a report released by MNI Indicators on Friday. MNI Indicators said its Chicago business barometer slumped to 45.7 in September from 52.2 in August, with a reading below 50 indicating contraction. Economists had expected the business barometer to edge down to 51.8.
Follow RTT